Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9NRD8

UPID:
DUOX2_HUMAN

ALTERNATIVE NAMES:
Large NOX 2; Long NOX 2; NADH/NADPH thyroid oxidase p138-tox; NADPH oxidase/peroxidase DUOX2; NADPH thyroid oxidase 2; Thyroid oxidase 2; p138 thyroid oxidase

ALTERNATIVE UPACC:
Q9NRD8; A8MQ13; D2XI64; Q9NR02; Q9UHF9

BACKGROUND:
The protein Dual oxidase 2, with alternative names such as NADPH thyroid oxidase 2 and p138 thyroid oxidase, is integral to thyroid hormone production and mucosal defense. It catalyzes the generation of hydrogen peroxide, necessary for thyroid peroxidase and lactoperoxidase functions. Its structure includes a peroxidase-like domain, indicating possible intrinsic peroxidase activity.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Thyroid dyshormonogenesis 6, due to gene variants affecting DUOX2, the protein stands as a key target for therapeutic intervention. Exploring DUOX2's function offers promising avenues for developing novel therapies for thyroid-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.